New drug combo for liver cancer after PD-1/PD-L1 treatment fails
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests three drugs (visugromab, nivolumab, lenvatinib) compared to a placebo plus lenvatinib for people with liver cancer (HCC) that cannot be removed or has spread, and who have already been treated with a PD-1/PD-L1 inhibitor without success. The goal is to see if the combination can help shrink tumors or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Liver cancer that cannot be removed surgically or has spread to other parts of the body
- You have tried only one prior treatment (a PD-1 or PD-L1 checkpoint inhibitor) for at least 12 weeks and it stopped working or you could not continue
- You are 18 or older
- You are in reasonably good health (ECOG performance status 0 or 1, and a Child-Pugh liver score of A6 or better)
- No other active cancers, serious heart problems, or inflammatory bowel conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs—TUDCA (a bile acid supplement), camrelizumab (an immunotherapy), and regorafenib (a targeted therapy)—for people with advanced liver cancer that has continued to grow after earlier immunotherapy plus Avastin treatment. The goal is to see if this new mix can help stop the cancer from growing.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of three treatments for advanced liver cancer that has not responded to immunotherapy: a chemotherapy delivered directly to the liver (HAIC), an immunotherapy drug (PD-L1), and a targeted therapy pill (Regorafenib). The goal is to see if this new combination can help control the cancer when the first immunotherapy stopped working.
This trial tests a combination of three treatments—chemo given directly into the liver, an oral targeted therapy, and an immunotherapy—for people with liver cancer that could be removed by surgery but isn't the first choice right now. The goal is to see if this combination can shrink the tumor and improve outcomes before surgery.
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a new combination of three drugs (SHR-8068, adebrelimab, and bevacizumab) against two standard immunotherapy combinations (sintilimab or atezolizumab plus bevacizumab) for people with advanced liver cancer who haven't had systemic treatment before. The goal is to see if the new combo works better for shrinking or controlling the cancer.
Hear when a new Unresectable or Metastatic Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.